24068-63-1

Basic information

• Product Name: 1-Butanol, 2-bromo-
• Synonyms: 2-Brom-butan-1-ol;2-bromo-butan-1-ol;2-Brom-1-butanol;2-Brom-butanol;1-Butanol,2-bromo;2-bromo-1-butanol;1-Butanol, 2-bromo-
• CAS NO: 24068-63-1
• Molecular Formula: C4H9BrO
• Molecular Weight: 153.019
• Mol File: 24068-63-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Butanol, 2-bromo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanol, 2-bromo-(24068-63-1)
• EPA Substance Registry System: 1-Butanol, 2-bromo-(24068-63-1)

Safety Data

• Hazardous Substances Data: 24068-63-1(Hazardous Substances Data)

Upstream product

• 3196-15-4 Methyl 2-bromobutyrate 
• 26074-52-2 2-bromo-butyryl bromide 
• 533-68-6 2-bromobutyric acid ethyl ester 
• 80-58-0 2-Bromobutyric acid 
• 106-88-7 ethyloxirane 

Downstream Products

• 1239921-42-6 2-bromobutyl benzyl(phenyl)carbamate 
• 106-88-7 ethyloxirane 

Relevant articles and documents

3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models

Cyclin-dependent kinases are therapeutic targets frequently deregulated in various cancers. By convenient alkylation of the 5-sulfanyl group, we synthesized 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with various substitutions at position 5 with potent antiproliferative activity in non-Hodgkin lymphoma cell lines. The most potent derivative 4.35 also displayed activities across more than 60 cancer cell lines. The kinase profiling confirmed high selectivity of 4.35 toward cyclin-dependent kinases (CDKs) 2, 5, and 9, and the cocrystal with CDK2/cyclin A2 revealed its binding in the active site. Cultured lymphoma cell lines treated with 4.35 showed dephosphorylation of CDK substrates, cleavage of PARP-1, downregulation of XIAP and MCL-1, and activation of caspases, which collectively confirmed ongoing apoptosis. Moreover, 4.35 demonstrated significant activity in various cell line xenograft and patient-derived xenograft mouse models in vivo both as a monotherapy and as a combination therapy with the BCL2-targeting venetoclax. These findings support further studies of combinatorial treatment based on CDK inhibitors.

Asymmetric alkyl-alkyl cross-couplings of unactivated secondary alkyl electrophiles: Stereoconvergent suzuki reactions of racemic acylated halohydrins

A method for asymmetric alkyl-alkyl Suzuki reactions of unactivated secondary alkyl electrophiles, specifically, cross-couplings of racemic acylated halohydrins with alkylborane reagents, has been developed. A range of protected bromohydrins, as well as a protected chlorohydrin and a homologated bromohydrin, are coupled in good ee by a catalyst derived from commercially available components.

CONVERSION OF EPOXIDES TO BROMOHYDRINS BY B-BROMOBIS(DIMETHYLAMINO)BORANE

Reaction of the title reagent with 1-alkene oxides regioselectively yields the corresponding 1-bromo-2-alkanols, while the more substituted bromide predominates in the cases of styrene oxide and 1-methylcyclohexene oxide.